Key Highlights
- LivaNova closed down 8.42% at $78.15 on August 5, despite beating estimates and raising full-year guidance.
- Second-quarter revenue reached $390.6 million, up 10.8% year-over-year, beating consensus estimates of $390.3 million by 2.70%.
- Adjusted EPS of $1.26 beat the $1.08 consensus estimate by 16.67%.
- Management raised full-year 2026 revenue guidance to $1.30 billion to $1.31 billion and adjusted EPS guidance to $4.30 to $4.40.
- The stock's decline came in a classic sell-the-news reaction after shares had run up to a 52-week high heading into the print.
What Happened
LivaNova (NASDAQ:LIVN) is a global medical technology company headquartered in London, United Kingdom, formed in 2015 through the merger of Sorin S.p.A. and Cyberonics, combining deep expertise in cardiovascular and neuromodulation therapies. The company operates through two core segments, Cardiopulmonary, which designs and manufactures heart-lung machines, oxygenators, autotransfusion systems, and perfusion accessories used in cardiac surgery, and Neuromodulation, which is best known for its VNS Therapy System, an implantable pulse generator that sends mild, regular pulses to the vagus nerve to treat drug-resistant epilepsy and difficult-to-treat depression.
Shares fell sharply despite the company beating headline earnings-and-revenue estimates and raising full-year guidance, in what several analysts described as a classic sell-the-news reaction after the stock had run up to a 52-week high heading into earnings. Second-quarter revenue reached $391 million, up 9.8% on a constant currency basis, with quarterly revenue and adjusted EPS of $1.26 both beating consensus estimates.
Beat and Raise Overshadowed by Valuation Reset
The company raised full-year 2026 guidance, with total revenue growth guidance raised to 8.5% to 10.5%, up from 7% to 9%, cardiopulmonary organic growth guidance raised to 9.5% to 10.5%, up from 8.5% to 9.5%, and epilepsy revenue growth guidance raised to 7% to 8%, up from 6% to 7%, driven by evergreen upgrades, oxygenator share gains, and improved US epilepsy reimbursement. Despite the strong print, a new Thermo Fisher supply agreement with oxygenator components and Needham raising its price target to $93, investors appeared to lock in profits after the stock's near-doubling in valuation already priced in the upside.
Segment performance showed cardiopulmonary revenue up 8% to 9% at the midpoint, driven by oxygenator upgrades, share gains, and improved reimbursement, while epilepsy revenue growth guided at 7% to 8% at the midpoint driven by neuromodulation accessory upgrades and share gains from improved reimbursement.
Manufacturing and Pipeline Updates
LivaNova signed a long-term supply agreement with Thermo Fisher Scientific for oxygenator components, addressing manufacturing constraints and supporting oxygenator portfolio and next-generation oxygenator development launched expected in 2026, with a new internal production line also on track to go live in second half of 2026. Adjusted free cash flow guidance was lowered to $150 million to $180 million from a prior $160 million to $180 million, due to increased capex for cardiopulmonary capacity scale-up and IT infrastructure investments.
On the pipeline front, the OSA next-generation MRI-compatible system PMA supplement submission timing shifted to between second half 2026 and first half 2027, and the 2030 OSA revenue target of $200 million to $400 million was unchanged, while new PolySync algorithm data showed approximately 85% cumulative AHI response rate.
Conclusion
LivaNova's beat-and-raise quarter, combined with a favorable manufacturing agreement and continued pipeline progress, presents a fundamentally strong picture, but the stock's steep run-up into the print left little room for anything short of a flawless result to sustain the rally. Today's pullback appears to reflect a valuation reset following the stock's near-doubling this year rather than any deterioration in the underlying cardiopulmonary or neuromodulation growth story.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...